New Recruiting Trial: An Open-Label Phase 2 Study of N-Acetyl-D-Mannosamine (ManNAc) in Subjects With Primary Focal Segmental Glomerulosclerosis

WHY IT MATTERS

This trial offers patients with primary FSGS access to an investigational treatment that may slow or stop kidney damage, with enrollment now open at sites participating in the National Human Genome Research Institute study.

Researchers are testing a new drug called ManNAc to treat primary focal segmental glomerulosclerosis (FSGS), a rare kidney disease that causes scarring and can lead to kidney failure. This is a Phase 2 trial, meaning the drug has already been tested for safety in a small group and now researchers want to see if it actually works to help patients. The trial is now accepting patients and is expected to start in April 2026.

NCT ID: NCT06664814 Title: An Open-Label Phase 2 Study of N-Acetyl-D-Mannosamine (ManNAc) in Subjects With Primary Focal Segmental Glomerulosclerosis Status: RECRUITING Phase: PHASE2 Sponsor: National Human Genome Research Institute (NHGRI) Start date: 2026-04-05 URL: https://clinicaltrials.gov/study/NCT06664814 Source: UniteRare clinical trials database

YOU CAN ACT ON THIS

If you have primary FSGS, check the trial website (clinicaltrials.gov/study/NCT06664814) to see if you meet eligibility requirements and locate participating sites near you, then discuss participation with your nephrologist.